Chinese Pulmonary Vascular Disease Research Group
15
5
5
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 15 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
20%
1 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
Development and Validation of a Chinese Quality of Life Scale for Pulmonary Arterial Hypertension
Role: lead
Portosystemic Shunt-associated Pulmonary Hypertension Multi-center Prospective Cohort Study
Role: lead
Artificial Intelligence-assisted Evaluation of Pulmonary HYpertension
Role: lead
the Application of Cardiopulmonary Exercise Testing in Assessment Outcome of Patients With Pulmonary Hypertension
Role: lead
CHASE Registry of Patients With Pulmonary Hypertension Receiving Targeted Therapy
Role: lead
A Real-World Registry Investigating TReprostInil sodiUM in Pulmonary Hypertension (Re-TRIUMPH)
Role: lead
Prevalence, Phenotypes, Predictors and Prognostic Implication of Obstructive Sleep Apnea in Pulmonary Hypertension
Role: lead
Safety and Efficacy of Balloon Pulmonary Angioplasty in China
Role: lead
Treatment of Patients With Takayasu Arteritis Complicated With Pulmonary Artery Involvement
Role: lead
Efficacy and Safety Evaluation of Tolvaptan in the Treatment of Patients With RHF Caused by PAH
Role: lead
Influence of Obstructive Sleep Apnea on the Severity of Coronary Artery Disease
Role: lead
The Effects of Obstructive Sleep Apnea and Its Intervention on Coronary Heart Disease
Role: lead
Evaluation of Association Between Obstructive Sleep Apnea and the Severity of Coronary Artery Disease
Role: lead
Clinical Characteristics of Acute Pulmonary Embolism in Chinese Population
Role: lead
Long-term Effects of CPAP on Lipidemia and Hs-CRP Levels in OSA Patients
Role: lead
All 15 trials loaded